What are the roles of dupilumab and oral cyclosporine in the treatment of pediatric atopic dermatitis (AD)?

Updated: Apr 26, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Dupilumab, a monoclonal antibody targeting the α-subunit of the interleukin (IL)–4 receptor to produce inhibition of both the IL-4 and IL-13 pathways, is of value in moderate-to-severe atopic dermatitis. [33, 34, 35, 36, 65, 66]

Oral cyclosporine has proven beneficial in patients with severe atopic dermatitis refractory to treatment with topical steroids. Discontinuation of cyclosporine frequently results in rapid relapse of skin disease. Significant adverse effects (eg, nausea, abdominal discomfort, hypertrichosis, paresthesias, hypertension, hyperbilirubinemia, renal impairment) have diminished enthusiasm for this drug, especially with the advent of the topical immunomodulators mentioned above.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!